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1. Introduction  
The rate of screening and treatment for osteoporosis remains low. Osteoporosis affects 
approximately 200 million women worldwide and two thirds of women 80 or older have 
this disease. It causes more than 1.6 million hip fractures worldwide. (International 
Osteoporosis Foundation, 2006) In the United States, more than 10 million Americans have 
osteoporosis and 3.6 million have low bone mineral density of the hip. In 2005 in the United 
States, there were more than 2 million osteoporotic fractures in men and women. These 
fractures caused more than 432,000 hospitalist admissions, 2.5 million physician office visits 
and about 180,000 nursing home admissions yearly in the United States. In 2005, the cost of 
osteoporotic fractures was approximately 17 billion dollars. (U.S. Department of Health and 
Human Services, 2004) Osteoporosis is responsible for approximately 90% of all spine and 
hip fractures in Caucasian females age 65-84 in the United States.  
Fifty percent of women and twenty-five percent of men greater than age 50 will experience 
an osteoporotic fracture in their remaining lifetime. (National Osteoporosis Foundation, Feb. 
2008) Less that 5 percent of patients with a clinical low trauma fragility fracture are referred 
for medical evaluation and treatment. (Bonura, 2009) In 2005, a population based study 
reported that the proportion of women screened and treated for osteoporosis after a fragility 
fracture was 10.2 percent and 12.9 percent respectfully. In males, studies indicate that a low 
proportion of men are evaluated for osteoporosis or receive anti-resorptive therapy after a 
fragility fracture. (Feldstein, 2005) Most patients with hip fractures receive no 
pharmacologic treatment for osteoporosis.  
Physician frequently fail to diagnose and treat osteoporosis, even in the elderly patients who 
have suffered a fractures. (Bonura, 2009) Less then 20 percent of women with wrist fractures 
are screened for osteoporosis, and only 12.9 percent are treated for osteoporosis after a facture. 
(Cuddihy, 2002)  In a clinical study the majority of patients with clinical vertebral fractures (80 
percent) did not receive osteoporosis therapy. (Lindsay, 2005) A prior osteoporotic fracture 
increases the risk of future fractures. A forearm fracture is associated with a two fold increased 
risk of fractures. Radiographic vertebral fractures are associated with a higher risk of 
subsequent hip and other fractures. In the year following a vertebral fracture, 26 percent of 
patients will fracture a hip, pelvis, vertebrae, wrist, humerus, or leg. (Klotzbuecher, 2000) 
Following a hip fracture in women, the mortality ranges between 20-24% within one year. 
25% of patients are admitted to a long term healthcare facility and only 40% are able to 
obtain their pre-fracture level of independence. Worldwide, one-third of hip fractures occur 
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in men and more men than women die after a hip fracture with a mortality rate of about 
37.5%. (Jiang, 2005) The most common of all the osteoporotic fractures are vertebral 
fractures. They are usually painless, but can cause back pain, height loss, deformity, 
reeducated respiratory function, disability, and a reduced quality of life. There is also an 
increase in mortality in women of about 23% over 8 years and they can cause an increase in 
future vertebral and non vertebral fractures. (Kado, 1999) 
 
 
Prior Fracture 
Relative Risk of Future Fractures 
Wrist Vertebral Hip 
Wrist 3.3 1.7 1.9 
Vertebral 1.4 4.4 2.3 
Hip Not Available 2.5 2.3 
Table 1. Prior Fracture as a Predictor of Fracture Risk (Klotzbuecher, 2000)) 
2. Evaluation  
Postmenopausal women and men after age 50 should be evaluated for their risk factors for 
osteoporosis and fracture, and their risk factors of falling. This evaluation includes a history 
and a physical exam, including a height measurement and, if necessary diagnostic testing. 
Several clinical risk factors for osteoporosis have been indentified and should be evaluated. 
Non-modifiable risk factors include advancing age, female sex, Asian or Caucasian 
ethnicity, history of a fracture as an adult, family history of a fracture in a first degree 
relative (maternal or paternal history of a hip fracture) and rheumatoid arthritis. Modifiable 
risk factors comprise low body weight, hormone deficiency, long term use of medications 
that affect bone homeostasis (e.g., glucocorticoids), causes of secondary osteoporosis, 
smoking, excessive alcohol consumption, an inactive lifestyle, and a lifetime diet low in 
calcium and vitamin D. The more risk factor that a patient has, the greater the risk of a 
fracture. (Bonura, 2009) 
The most important of all these risk factors are age (65 or greater in women and 70 or 
greater in men) and the occurrence of a low trauma fracture after age 40. Other risk factors 
of importance are bone mineral density, genetics, menopause, BMI, and lifestyle. 
As a woman ages, their fracture risk increases. After age 50, their fracture risk doubles every 
7 or 8 years. The average age of a hip fracture in women is 82 years and in men 50% of their 
hip fractures occur before age 80. Vertebral fractures usually occur in women and men in 
their seventies. (Chang, 2004) A prior osteoporotic fracture increases the risk of future 
osteoporotic fracture risk. If a postmenopausal female sustains an osteoporotic fracture, she 
has approximately a two fold increase of sustaining another osteoporotic fracture in her 
lifetime. 
Bone mineral density also is a risk factor for future fractures. Bone mineral density affects 
fracture risk. The lower the bone mineral density (BMD), the higher the risk for fractures. A 
decrease of 1 standard deviation of bone mineral density (BMD) represents a 10-12% 
decrease in BMD and can increase fracture risk by 1.5 to 2.6 times. (Marshall, 1996) Genetics 
plays a role in osteoporosis and future fracture risk. Daughters of women who have had an 
osteoporotic fracture, and daughters of first degree relatives (mother or sisters) or have 
osteoporosis have lower bone mineral density (BMD) for their age. Also a history of an  
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Lifestyle Factors
Low calcium intake Vitamin D insufficiency Excess vitamin A
High caffeine intake High salt intake Aluminum (in antacids) 
Alcohol (3 or more drinks/d) Inadequate physical activity Immobilization
Smoking (active or passive) Falling Thinness
Hypogonadal States
Androgen insensitivity Hyperprolactinemia Premature ovarian failure 
Anorexia nervosa and 
bulimia 
Panhypopituitarism Turner’s & Klinefelter’s 
syndromes 
Athletic amenorrhea
Endocrine Disorders
Adrenal insufficiency Diabetes mellitus Thyrotoxicosis
Cushing’s syndrome Hyperparathyroidism
Gastrointestinal Disorders
Celiac disease Inflammatory bowel disease Pancreatic disease 
Gastric bypass Malabsorption Primary biliary cirrhosis 
GI surgery 
Genetic Factors 
Cystic fibrosis Homocystinuria Osteogenesis imperfecta 
Ehlers-Danlos Hypophosphatasia Parental history of hip fracture 
Gaucher’s disease Idiopathic hypercalciuria Porphyria
Glycogen storage diseases Marfan syndrome Riley-Day syndrome 
Hemochromatosis Menkes steely hair syndrome
Hematologic Disorders
Hemophilia Multiple myeloma Systemic mastocytosis 
Leukemia and lymphomas Sickle cell diseases Thalassemia
Rheumatic and Autoimmune Diseases
Ankylosing spondylitis Lupus Rheumatoid arthritis 
Miscellaneous Conditions and Diseases
Alcoholism Emphysema Muscular dystrophy 
Amlyloidosis End stage renal disease Parenteral nutrition 
Chronic metabolic acidosis Epilepsy Post-transplant bone disease 
Congestive heart failure Idiopathic scoliosis Prior fracture as an adult 
Depression Multiple sclerosis Sarcoidosis
Medications 
Anticoagulants (heparin) Cancer chemotherapeutic 
drugs 
Glucocorticoids (≥ 5 mg/d of 
prednisone or equivalent for ≥ 
3 mo) 
Anticonvulsants Cyclosporine A and 
tacrolimus 
Gonadotropin releasing 
hormone agonists 
Aromatase inhibitors Depo-medroxyprogesterone Lithium
Barbiturates 
Table 2. Conditions, Diseases and Medications That Cause or Contribute to Osteoporosis 
and Fractures (National Osteoporosis Foundation, 2008) 
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osteoporotic fracture in a first degree relative increases an individual’s risk of osteoporotic 
fractures. (Seaman, 1989) During the late menopausal transition (2-3 years before 
menopause) and during menopause, there is an increase in bone resorption due to a 
decrease in estrogen production. Women lose approximately 2% of BMD annually for about 
5 years during menopause. After which they lose 1-2% per year. They can lose 10.5% in their 
spine and 5.3% in their hip over this 5-7 year period in this time. (Recker, 2000) In men bone 
loss increases after age 70 and it is more common in men who are deficient in testosterone or 
estradiol. (Fink, 2006) 
If a woman is thin, a weight of less than 127 pounds, it is a risk factor for a low BMD and a 
high risk for fracture, A high BMI may be protective. In older women, low BMI is associated 
with a higher fracture risk. (Van Der Voort, 2001) 
The lifestyle factors that are associated with low bone mass and fracture risk are cigarette 
smoking, alcoholism, poor nutrition, and lack of physical activity, There are also secondary 
causes of low bone mineral density, including medications, genetic disorders, and various 
disease states.  
Also, in all menopausal women and men after age 50, their risk for falls should be evaluated. 
About one-third of men and women age 65 years of age or older fall each year. They should be 
questioned about their history of falls, muscle weakness, dizziness, difficulty walking, 
impaired vision, balance problems, or medications that affect balance (e.g., sedatives, narcotics, 
anti-hypertensives). Some of the medications that have the highest association with falls are 
the serotonin-reuptake inhibitors, antiarrhythmic drugs, tricyclic antidepressants, neuroeleptic 
agents, benzodiazepines, and the anticonvulsants. (Leipzig, 1999) Ten percent of these falls 
result in hip fractures and 90% of hip fractures are due to falls. An excellent screening test is 
the “Get Up and Go” test. Have a senior patient get up from a chair, without using their arms, 
and then have them walk and observe for unsteadiness. (Mathias, 1986) The more number of 
risk factors of falling, the greater risk of falls. 
 
Medical Risk Factors
Age Medications causing over-sedation (narcotic analgesics, 
anticonvulsants, psychotropics)
Anxiety and agitation Orthostatic hypotension
Arrhythmias Poor vision and use of bifocals
Dehydration Previous fall
Depression Reduced problem solving and mental acuity and 
diminished cognitive skills
Female gender Urgent urinary incontinence
Impaired transfer and mobility Vitamin D insufficiency [serum 25-hydroxyvitamin D 
(25(OH)D) < 30 ng/ml (75 nmol/L)]
Malnutrition 
Environmental Risk Factors Neuro and Musculoskeletal Risk 
Factors
Other Risk Factors 
Lack of assistive devices in 
bathrooms 
Kyphosis Fear of falling 
Loose throw rugs Poor balance
Low level lighting Reduced proprioception
Obstacles in the walking path Weak muscles
Slippery outdoor conditions
Table 3. Risk Factors for Falls (National Osteoporosis Foundation, 2008) 
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During a patient’s examination, height measurement may be useful to indicate occult 
vertebral compression fractures, which are indicative of osteoporosis. They are the most 
common osteoporotic fractures in postmenopausal women, and two-thirds of these fractures 
are not clinically recognized. (Cauley, 2007) The loss of height, kyphosis, and back pain may 
be signs of vertebral fractures. Normally after achieving maximal height, women can lose up 
to 1.0 – 1.5 inches (2.0 – 3.8 cm) of height as part of the normal aging process, due to 
degenerative arthritis and shrinkage of intervertebral disks. Height loss of greater than 1.5 
inches (3.8 cm) increases the risk of a vertebral fracture. One must suspect a vertebral 
fracture in postmenopausal women with a historical height loss greater than 4 cm (1.6 in.) or 
a prospective height loss greater than 2 cm (0.8 in.). In men, a historical height loss greater 
than 6 cm (2.4 in.) or a prospective height loss greater than 3 cm (1.2 in.). Vertebral fractures 
are associated with an increase of vertebral and nonvertebral fractures in the future. 
Nineteen percent of patients who have a vertebral fracture will sustain another fracture 
within one year. (Laster, 2007) Across a range of BMD, prevalent vertebral fractures increase 
fracture risk by up to 12 times. Risk assessments based only on BMD may overestimate the 
risk of future fractures in patients without vertebral fractures and under estimate the risk of 
future fractures in patients with vertebral fractures. (Siris, 2007)  When measuring height 
annually, it should be performed with a stadiometer or a wall mounted ruler. If there is a 
historical height loss of more than 1.5 inches (3.8 cm) in menopausal women or than 2.4 
inches (6 cm) in men, an evaluation to rule out vertebral fractures should be performed. This 
can be accomplished by a vertebral fracture assessment (VFA) or by a lateral thoracolumbar 
radiograph. It is also important in patients who have acute or chronic back pain or kyphosis 
(to rule out vertebral fractures).  
3. Bone mineral density assessment  
The diagnosis of osteoporosis is made by BMD. The decision to assess bone density should 
be based on the skeletal health and risk profile of the individualized patient. Table 4 and 5 
summarizes the Internal Society of Clinical Densitometry and the North American 
Menopausal Society indications for Bone Mineral Density (BMD). 
 
Indications for Bone Mineral Density (BMD) Testing – ISCD
Women aged 65 and older Adults with a disease or condition associated 
with low bone mass or bone loss
Postmenopausal women under age 65 with 
risk factors for fracture
Adults taking medications associated with 
low bone mass or bone loss
Women during the menopausal transition 
with clinical risk factors for fracture, such as 
low body weight, prior fracture or high-risk 
medication use 
Anyone being considered for pharmacologic 
therapy 
Men aged 70 and older Anyone being treated, to monitor treatment 
effect
Men under age 70 with clinical risk factors 
for fracture 
Anyone not receiving therapy in whom 
evidence of bone loss would lead to treatment 
Adults with a fragility fracture Women discontinuing estrogen should be 
considered for bone density testing according 
to the indications listed above
Table 4. Indications for Bone Mineral Density (BMD) Testing - ISCD (Baim, 2008)) 
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Indications for Bone Mineral Density (BMD) Testing - NAMS 
BMD Should Be Measured in the Following 
Populations:  
Testing should be considered for 
postmenopausal women age 50 and over 
when one or more of the following risk 
factors for fracture have been identified 
 All women age 65 and over regardless of 
clinical risk factors 
 Fracture (other than skull, facial bone, 
ankle, finger, and toe) after menopause 
 Postmenopausal women with medical 
causes of bone loss (eg, steroid use, 
hyperparathyroidism), regardless of age 
 Thinness (body weight < 127 lbs. [57.7 kg] 
or BMI < 21 kg/m2) 
 Post menopausal women age 50 and over 
with additional risk factors (see below) 
 History of hip fracture in a parent 
 Postmenopausal women with a fragility 
fracture (eg, fracture from a fall from 
standing height) 
 Current smoker 
 Rheumatoid arthritis 
 Alcohol intake of more than two units per 
day (one unit is 12 oz. of beer, 4 oz. of 
wine, or 1 oz. of liquor) 
Table 5. Indications for Bone Mineral Density (BMD) Testing of the North American 
Menopause Society (NAMS) (North American Menopause Society, 2010) 
There are many techniques that measure BMD. The gold standard in diagnosis of 
osteoporosis is made by central DXA using dual energy absorptiometry. Using two different 
x-ray energies, a DXA device can record attenuation profiles at two different photon 
energies. At low energy (30-50 keV) bone attenuation is greater than soft tissue attenuation; 
where as high energy (greater than 70 keV) bone attenuation is similar to soft tissues 
attenuation. Thus, two types of tissue are distinguished: bone (hydroxyapatite) and soft 
tissue (everything else). (International Society of Clinical Densitometry, 2010) DXA 
measures areal BMD. The results are reported as grams of mineral per square centimeter 
(g/cm2). 
The skeletal sites that are measured with central DXA are both the PA spine (L1 – L4) and the 
hip (femoral neck or total proximal femur of either hip). In certain circumstances when a hip 
or a spine cannot be measured then a forearm (33% radius or one third radius of the non 
dominant arm) should be measured (e.g., patients who are obese and whose weight is above 
the limit of the DXA table). Results of DXA are reported as a comparison of two norms. A T-
score uses a Caucasian female 20-29 NHANES III database, for women of all ethnic groups. 
In men, a Caucasian male 20-29 NHANES III database is used in all ethnic groups. The 
difference between the patient’s score is expressed in standard deviation above or below the 
norm. Also, a Z-score will be generated. The patient’s BMD is compared to individuals of 
the same age, sex, and ethnicity. Z-scores should be population specific where adequate 
reference data exists (International Society for Clinical Densitometry, 2009). 
The lower the BMD (T-score) the higher the fracture risk. A decrease of 1 standard deviation 
represents a 10 - 12% decrease in BMD and an increase in fracture risk by a factor of 1.5 to 
2.6, depending on fracture type.  The risks of spine and hip fracture increase 2.3 fold and 2.6 
fold respectively, for each decrease of 1 standard deviation at the spine and hip. A Z-score  
of -2.0 or lower is defined as below expected range for age. A Z-score above -2.0 is within 
the expected range for age.  
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Peripheral Dual Energy X-Ray Absorptiometry (pDXA) measures areal bone density of the 
forearm, finger, or heel. It can indentify individuals at risk for fracture but this modality 
cannot be used for the diagnosis of osteoporosis or for follow up of patients. The measurement 
of peripheral sites are useful only in screening patients for the need of a central DXA, they are 
not useful for follow up in patients or in patients taking medications for osteoporosis. (Recker, 
2000) Quantitative Computed Tomography (QCT) can measure spinal BMD and can predict 
vertebral fractures in women, but there is a lack of evidence of a prediction of vertebral 
fractures in men. There is no evidence that spine QCT can predict hip fractures in women or 
men. Peripheral Quantitative Computed Tomography (pQCT) of the ultra distal radius can 
predict hip fracture risk, but not spine fracture risk in postmenopausal women. Quantitative 
Ultrasound (QUS) can predict fragility fractures in postmenopausal women (hip and 
vertebral) and men over age 65 (hip and nonvertebral fractures). (Baim, 2008) 
According to the World Health Organization (WHO) only the measurement of BMD by 
central DXA can be used for the diagnosis of osteoporosis, the follow up of individuals and 
the monitoring of treatment efficacy. (National Osteoporosis Foundation, 2008) 
The WHO has defined low bone mass (Osteopenia) as a BMD between -1.0 and 2.5 SD below 
the normal for young healthy adults of the same sex (T-score < 1.0 and > -2.5), osteoporosis 
by a BMD of -2.5 SD or below (T-score ≤ -2.5) and severe osteoporosis with a T-score of ≤ -
2.5 and a fragility fracture. (World Health Organization, 2003) 
 
The World Health Organization has established the following definitions based on 
BMD measurement at the spine, hip, or forearm by DXA devices: 
Normal Low Bone Mass (Osteopenia) Osteoporosis 
BMD is within 1 SD 
of a “young 
normal” adult (T-
score at -1.0 and 
above. 
BMD is between 1.0 and 2.5 SD 
below that of a “young 
normal” adult (T-score 
between -1.0 and -2.5). 
BMD is 2.5 SD or more below that of a 
“young normal” adult (T-score at or 
below -2.5). Patients in this group 
who have already experienced one or 
more fracture are deemed to have 
severe or “established” osteoporosis.” 
Note: Although these definitions are necessary to establish the presence of osteoporosis, they should 
not be used as the sole determinant of treatment decisions. 
Table 6. Defining Osteoporosis by BMD (Kanis, 1994) 
In postmenopausal women and men age 50 and older, T-scores are preferred, using the 
WHO criteria. In women prior to menopause and in males younger than age 50, Z-scores, 
not T-scores are preferred. The WHO diagnostic criteria may be applied to women in the 
menopausal transition with risk factors for osteoporosis. 
At the time of a central DXA, a vertebral fracture assessment (VFA) can be performed. It is a 
densitometric spine imaging than can detect vertebral fractures. (Schousboe, 2008) Most 
vertebral fractures are asymptomatic and if present can increase an individual’s future risk 
of fracture. A Vertebral Fracture Assessment (VFA) is a diagnostic method in which low 
intensity or dual x-ray absorptiometry is used to examine the lateral spine (T4-L4), thereby 
identifying vertebral fractures. (Leipzig, 1999) There is much less radiation with a VFA in 
comparison to a lateral spine x-ray (3µSV for VFA versus 600µSV for a radiograph).  
According to the International Society of Clinical Densitometry a vertebral fracture 
assessment should be performed in the following circumstances: 
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Consider VFA when results may influence management. 
Postmenopausal women with low bone 
mass (Osteopenia) by BMD criteria PLUS 
any one of the following: 
Men with low bone bass (Osteopenia) by 
BMD criteria, PLUS any one of the 
following: 
 Age greater than or equal to 70 years  Age 80 years or older 
 Historical height loss greater than 4 cm 
(1.6 in.) 
 Historical height loss greater than 6 cm 
(2.4 in.) 
 Prospective height loss greater than 2 cm 
(0.8 in.) 
 Prospective height loss greater than 3 cm 
(1.2 in.) 
 Self-reported vertebral fracture (not 
previously documented) 
 Self-reported vertebral fracture (not 
previously documented) 
 Two or more of the following:  Two or more of the following: 
 Age 60 to 69 years  Age 70 to 79 years 
 Self-reported prior non-vertebral 
fracture 
 Self-reported prior non-vertebral 
fracture 
 Historical height loss of 2 to 4 cm  Historical height loss of 3 to 6 cm 
 Chronic systemic diseases associated 
with increased risk of vertebral 
fractures (e.g., moderate to severe 
COPD or COAD, seropositive 
rheumatoid arthritis, Crohn’s disease)
 Chronic systemic diseases associated 
with increased risk of vertebral 
fractures (e.g., moderate to several 
COPD or COAD, seropositive 
rheumatoid arthritis, Crohn’s disease 
 On pharmacologic androgen deprivation 
therapy or following orchiectomy 
Women or men on Chronic Glucocorticoid 
therapy (equivalent to 5 mg or more of 
prednisone daily for three (3) months or 
longer). 
Postmenopausal women or men with 
osteoporosis by BMD criteria, if 
documentation of one or more vertebral 
fractures will alter clinical management. 
Table 7. Indications for VFA (Schousboe, 2008) 
The VFA is interpreted using a semi-quantitative visual inspection with assignment of 
fracture grade by the radiologist or the clinician. Using Genant’s method, the clinician 
determines if a vertebra is fractured or normal. The thoracic and lumbar spine is scanned for 
deformities and height loss exceeding twenty percent in the anterior, middle, or posterior 
dimensions. What the clinician determines visually using the semiquantitative method of 
Genant are morphological changes in the vertebrae. Clinicians should look for end plate 
deformities (horizontal edges), lack of parallelism of the end plates, buckling of the cortices 
(vertical edges) and loss of vertical continuity with the adjacent vertebrae. Clinicians then 
grade the fracture deformity. If a fracture is suspected, it is compared to a standard: 
 Grade 1 (mild fracture) height loss 20-25% 
 Grade 2 (moderate) height loss of 25-40% 
 Grade 3 (severe) height loss of > 40% 
Depending on where deformities are present in the vertebra, fractures are classified as 
wedge (loss of anterior height), crush (loss of posterior height) and biconcave (loss of middle 
height). (Genant, 1993) 
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In a study comparing VFA to spine radiographs, VFA had a sensitivity of 95% to detect 
vertebral fractures indentified by spine radiographs and a specificity of 82% to exclude 
fractures not visualized in a radiograph. (Vokes, 2003) 
 
 
Fig. 1. Genant’s Semiquantitative Analysis Grading of Fracture Deformity (Genant, 1993) 
4. Follow up bone mineral density testing  
Follow up DXA testing by central DXA should be performed every 2-5 years in untreated 
menopausal women and in men age 70 or older. In patients who are receiving osteoporosis 
therapy, BMD testing should be performed every 1-2 years. (Van Der Voort, 2001) In order 
to determine if the change in BMD over time is a real biological change and not to due to 
chance, a precision study must be performed. Each DXA facility should determine its 
precision error and calculate the least significant change (LSC), within a 95% statistical 
confidence. The precision error that is supplied by the manufacturer should not be used. 
To perform a precision analysis, the technologist measures 15 patients 3 times or 30 patients 
2 times, repositioning the patient after each scan. They then calculate the root mean square 
stand deviation and obtain the LSC at 95% confidence. This is a real biological change over 
time and is not due to chance.  The minimum acceptable precision for an individual 
technologist is: lumbar spine 1.9% (LSC = 5.3%), total hip 1.8% (LSC = 5.0%), and femoral 
neck 2.5% (LSC = 6.9%). (International Society for Clinical Densitometry, 2007) 
5. Evaluation for treatment  
Within one year of a hip fracture 10-20% of patients die, 20% are placed in nursing homes, 
and only 40% regain independent functioning. (U.S. Department of Health and Human 
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Services, 2004) There are more low-trauma fractures in patients with low bone density 
(Osteopenia) than in those with a DXA diagnosis of osteoporosis. This occurs because there 
are more individuals with Osteopenia than osteoporosis. (Khosla, 2007) In the study of 
osteoporotic fractures (SOF), 54% of women with hip fractures did not have osteoporosis 
according to their BMD results. (Wainwright, 2005)  Therefore, it is important to identify 
and treat individuals who have Osteopenia (low bone density) who have the highest chance 
of a fracture. Not all patients with low bone mass will fracture. 
6. FRAX assessment tool  
The WHO sponsored the development of the FRAX assessment tool to indentify which 
individuals with low bone mineral density have the greatest chance of fracture and which 
patients need to be treated. (Kanis, 2008) It identifies which patients, who have Osteopenia 
(low bone lass) who have a higher fracture risk and need to be treated. (Internal Society for 
Bone Densitometry Course) FRAX is based on an analysis of approximately 60,000 patients 
that were studied in Europe, North American, Asia, and Australia. The FRAX tool is for 
untreated individuals with low bone density and indentifies which individuals are at the 
highest risk of fracture. The NOF recommends the FRAX tool for untreated postmenopausal 
and men 50 or more years of age with a T-score in the osteopenic range (low bone mass). 
FRAX predicts the 10 year probability for hip fracture and for major osteoporotic fractures 
(hip, proximal humerus, distal forearm, and clinical vertebral fractures). FRAX uses clinical 
risk factors with or without femoral neck BMD. Economic modeling was performed to 
indentify the 10 year hip fracture risks above which is cost effective, from the societal 
perspective, to treat with pharmacological agents. 
NOF criteria for using FRAX to assist with treatment decisions are: 
a. An untreated postmenopausal women or a man age 50 or older 
b. With low bone mass (T-score between -1.0 and -2.5) 
c. With no prior hip or vertebral fracture (clinical or morphometric) 
d. An evaluable hip for DXA study 
Examples of “untreated” patients include: 
a. No ET/HT or estrogen agonist/antagonist (SERM) for the past one year 
b. No calcitonin for the past one year 
c. No PTH for the past one year 
d. No denosumab for the past one year 
e. No bisphosphonate for the past two years (unless it is an oral taken for < 2 months) 
This model uses femoral neck BMD but, in women, if femoral neck BMD is unavailable, total 
hip BMD may be used. In men, only femoral neck BMD can be used in FRAX. (World Health 
Organization, 2003) Spine of peripheral BMD measurements should not be used in FRAX. 
(Kanis) There are multiple limitations of FRAX. It does not consider the other risk factors for 
fracture. These include a history of falls, patients with clinical vertebral fractures, doses of 
glucocorticoids, exposure dose of alcohol, nicotine, drugs which lower BMD (anticonvulsants, 
anticoagulants, antineoplastics, antiestrogenic or antiandrogenic agents), parental history of 
non hip fractures and lumbar spine BMD. This tool only recognizes a hip fracture of a parent. 
Spinal fractures of a parent due to osteoporosis also may increase fractures risk in the 
offspring. The therapeutic thresholds that are proposed in the FRAX tool are for clinical 
guidance and are not rules. They do not preclude clinicians from considering intervention 
strategies in patients who do not have osteoporosis, nor should they mandate treatment in 
patients with osteopenia. The decision to treat a patient must be made on a case by case basis. 
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Risk Factor Type of Variable Description
Age Continuous 40-90 years. For ages below or above this 
range, the model computes fracture risks as of 
age 40 or 90.
Sex Male/female Model validated for men and women. 
Weight Continuous Expressed in kilograms.
Height Continuous Expressed in centimeters. The modal calculates 
body mass index and uses it as a continuous 
variable.
Previous fracture Yes/no Includes adult fractures occurring 
spontaneously or with low trauma (e.g., 
osteoporosis-related fractures), including 
morphometric vertebral fractures. 
Parental hip fracture Yes/no Any hip fracture affecting either parent. 
Current smoking Yes/no Dose-dependence of fracture risk has been 
observed but is not reflected in the model. 
Oral glucocorticoid use Yes/no Present or past exposure to doses equivalent to 
5 mg/d prednisolone for ≥ 3 months. Dose-
dependence of fracture risk has been observed 
but is not reflected in the model.
Rheumatoid arthritis Yes/no Only a confirmed diagnosis of rheumatoid 
arthritis should be scored.
Secondary osteoporosis Yes/no Secondary osteoporosis occurs in the presence 
of conditions including, but not limited to, 
insulin-dependent diabetes, adult osteogenesis 
imperfecta, uncontrolled hyperthyroidism, 
menopause at 45 years, hypogonadism, 
chronic malnutrition/malabsorption, or 
chronic liver disease.
Alcohol ≥ 3 units daily Yes/no 1 unit is 285 mL beer, 120 mL wine, 60 mL 
aperitif, or 30 mL distilled spirits. Dose-
dependence of fracture risk has been observed 
but is not reflected in the model.
Femoral neck BMD Continuous Enter BMD value and select DXA machine 
model used to obtain it, or enter T-score. Risk 
estimates can also be produced without BMD. 
If only total hip BMD is available, that can be 
used. Spinal or peripheral BMD are not to be 
used.
Clinical vertebral fractures and multiple osteoporosis-related fractures confer additional 
risk beyond what the model calculates; clinical judgment should be used.
For a “yes” answer to smoking, alcohol, or glucocorticoid use, the model assumes average 
levels of exposure. With high exposures, facture risk may increase more than the model 
accounts for, and clinical judgment should be used.
When a femoral neck T-score is entered into the online FRAX model, the secondary 
osteoporosis button becomes inactivated.
Table 8. Risk Factors Included in the FRAX Algorithm (Siris, 2010) 
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Fig. 2. FRAX Calculation Tool 
7. Whom should we treat: NOF guidelines  
Consider FDA approved medical therapies for patients with: 
 A hip or vertebral (clinical or morphometric) fracture 
 Osteoporosis diagnosed by a BMD T-score ≤ -2.5 (femoral neck or spine) after 
appropriate evaluation to exclude secondary causes of osteoporosis 
 Low bone density (a BMD score between -1 and -2.5 at the femoral neck or spine) and a 
FRAX 10 year probability of hip fracture ≥ 3% or a major osteoporotic fracture (hip, 
wrist, proximal humerus, clinical vertebral fracture) of ≥ 20% 
Physicians should use clinical judgment to treat patients at lower FRAX risk levels if 
additional risk factors for fracture are present. 
Before developing a management plan, the clinician should rule out secondary causes of 
osteoporosis or bone loss. About 20% of postmenopausal women with osteoporosis and 40% 
of men with osteoporosis have a secondary cause that can be indentified and treated. 
(Fitzpatrick, 2002) Secondary osteoporosis can result from a variety of medical conditions 
including endocrine, hematopoietic or nutritional disorders, and vitamin D deficiency. 
Diseases such as celiac (malabsorption), liver and renal diseases, the use of glucocorticoids, 
aromatase inhibitors, antiandrogen therapy (GNRH) and chemotherapy can cause bone loss. 
These secondary causes must be ruled out before staring pharmacological therapy. 
Some of the routine tests would be a complete blood count, serum levels of calcium and 
phosphate, 25-hydroxyvitamin D, bone specific alkaline phosphatase, creatinine and a 24-hour 
urine for calcium. Some of the specialized tests may include a thyroid stimulating hormone 
(TSH), serum levels of parathyroid hormone (PTH) to screen for hyperparathyroidism, a 
serum protein electrophoresis to indentify abnormal protein produced by multiple myeloma 
and antitissue transglutaminase antibodies for celiac disease. (Hodgson, 2003) 
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Test Diagnostic Result Possible Secondary Cause 
Completed blood cell count Anemia Multiple myeloma 
Serum calcium Elevated Hyperparathyroidism 
 Low Vitamin D deficiency, 
Gastrointestinal (GI) 
malabsorption 
Serum phosphate Elevated Renal failure
 Low Hyperparathyroidism 
Serum 25-hydroxyvitamin D Low Undersupplemenataion, GI 
malabsorption, celiac disease 
Serum albumin Used to interpret serum 
calcium, nutritional 
deficiencies 
Serum alkaline phosphatase Elevated Vitamin D deficiency, GI 
malabsorption, 
hyperparathyroidism, Paget’s 
disease, liver/biliary disease 
Urinary calcium excretion Elevated Renal calcium leak, multiple 
myeloma, metastatic cancer 
involving bone, 
hyperparathyroidism, 
hyperthyroidism 
 Low GI malabsorption, inadequate 
intake of calcium and vitamin D 
Thyroid-stimulating hormone 
(TSH) 
Low Hyperthyroidism (causes excess 
bone turnover) 
 High Hypothyroidism
Serum protein electrophoresis Monoclonal band Multiple myeloma 
Tissue transglutaminase 
antibody (gluten enteropathy) 
Elevated Predictive of celiac disease 
Creatinine Elevated Renal osteodystrophy, possible 
contraindication to 
bisphosphonates 
PTH Elevated Hyperparathyroidism, vitamin 
D deficiency 
Table 9. Laboratory Tests for Osteoporosis Evaluation (North American Menopause Society, 
2010) 
8. Bone turnover markers  
Bone turnover markers are proteins that are produced by the activity of osteoclasts and by 
osteoblasts. The resorption markers of osteoclastic activity are the breakdown products of 
type I collagen (N-telopeptides, C-telopeptides, deoxypyridinolone). There are markers of 
osteoblastic synthesis of bone matrix (bone-specific alkaline phosphatates, osteocalcin, 
procollagen type I N-terminal propetide). 
www.intechopen.com
 
Osteoporosis 
 
130 
Suppression of biochemical markers of bone turnover occur 3-6 months of specific 
antiresorptive therapies and they increase after 1-3 months of anabolic therapies. The NOF 
recommends a baseline and a repeat bone resorption marker after initiation of therapy as a 
method of monitoring the therapeutic effect of an antiresportive agent.  
The changes of bone turnover markers occur more rapidly than changes in BMD and they 
can also predict patient compliance or poor response to antiresorptive therapy. There is a 
high degree of biological and analytical variability in the measurement of biochemical 
markers. This variability can be reduced by obtaining samples in the early morning after an 
overnight fast. (National Osteoporosis Foundation, 2008) 
9. Conclusion  
In all senior men and in all postmenopausal women a history should be obtained to evaluate 
a patient’s risk factors for osteoporosis and for fractures. As part of a patient’s physical 
exam, a height measurement should be performed. This can indentify when there is a 
significant height loss or an asymptomatic vertebral fracture. When necessary, a central 
DXA and sometimes a Vertebral Fracture Assessment (VFA) may be performed. Clinicians 
should estimate a patient’s 10-year probability of a hip or a major osteoporotic related 
fracture using FRAX. We should use the WHO criteria to determine who we should treat 
and which individuals whom we should not treat. Clinicians also must perform a laboratory 
workup on patients, to rule our secondary causes of osteoporosis, before starting a 
pharmacological treatment regimen. 
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